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Sigma-1 receptor antagonism increases the effects of morphine on nociceptive pain,
even in morphine-tolerant animals. However, it is unknown whether these receptors
are able to modulate morphine antinociception and tolerance during inflammatory pain.
Here we used a mouse model to test the modulation of morphine effects by the
selective sigma-1 antagonist S1RA (MR309), by determining its effect on inflammatory
tactile allodynia (von Frey filaments) and on grip strength deficits induced by joint
inflammation (a measure of pain-induced functional disability), and compared the results
with those for nociceptive heat pain recorded with the unilateral hot plate (55◦C) test.
The subcutaneous (s.c.) administration of morphine induced antinociceptive effects
to heat stimuli, and restored mechanical threshold and grip strength in mice with
periarticular inflammation induced by Complete Freund’s Adjuvant. S1RA (80 mg/kg,
s.c.) administered alone did not induce any effect on nociceptive heat pain or
inflammatory allodynia, but was able to partially reverse grip strength deficits. The
association of S1RA with morphine, at doses inducing little or no analgesic-like effects
when administered alone, resulted in a marked antinociceptive effect to heat stimuli
and complete reversion of inflammatory tactile allodynia. However, S1RA administration
did not increase the effect of morphine on grip strength deficits induced by joint
inflammation. When S1RA (80 mg/kg, s.c.) was administered to morphine-tolerant
animals, it rescued the analgesic-like effects of this opioid in all three pain measures.
However, when S1RA was repeatedly given during the induction of morphine tolerance
(and not on the day of behavioral evaluation) it failed to affect tolerance to the
effects of morphine on nociceptive heat pain or inflammatory allodynia, but completely
preserved the effects of this opioid on grip strength deficits. These effects of S1RA on
morphine tolerance cannot be explained by pharmacokinetic interactions, given that
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the administration of S1RA did not modify concentrations of morphine or morphine-3-
glucuronide (a major morphine metabolite) in morphine-tolerant animals in plasma or
brain tissue. We conclude that sigma-1 receptors play a pivotal role in the control of
morphine analgesia and tolerance in nociceptive and inflammatory pain, although in a
manner dependent on the type of painful stimulus explored.
Keywords: sigma-1 receptors, morphine, pain, analgesia, tolerance, joint inflammation, grip strength, von Frey
threshold
INTRODUCTION
Inflammatory pain is characterized by a decrease in the
cutaneous sensory threshold, and by pain-induced decreases
in physical function, which affect the quality of life of
patients with inflammatory conditions (Salaffi et al., 2009).
Cutaneous mechanical thresholds and physical function can
be measured, in both humans and rodents, with von Frey
filaments (cutaneous sensitivity) and grip strength testing
(physical function) (Chandran et al., 2009; Cobos and Portillo-
Salido, 2013; Lee, 2013; Helfert et al., 2015). Alterations in von
Frey thresholds and pain-induced grip strength deficits during
inflammation result (at least partially) from non-overlapping
mechanisms, including the involvement of different subsets of
primary afferents (Montilla-García et al., 2017). Despite their
differences, both of these outcomes are sensitive to opioid
analgesics, which can restore both normal sensory thresholds and
physical functioning (Montilla-García et al., 2017).
Sigma-1 receptors are a promising novel pharmacological
target for pain treatment (Romero et al., 2016; Sánchez-
Fernández et al., 2017). Among the selective sigma-1 antagonists,
the best characterized is S1RA, also known as MR309 (Vela
et al., 2015). This compound is the only sigma-1 antagonist
which has been evaluated in clinical trials with an intended
indication for pain relief. S1RA has already been evaluated
with positive results in several Phase II clinical trials for
neuropathic pain (Bruna et al., 2018). Preclinical studies have
shown that sigma-1 inhibition enhances the antinociception
induced by opioid drugs, including morphine (reviewed in
Zamanillo et al., 2013; Sánchez-Fernández et al., 2017). In
addition, sigma-1 antagonism is able to rescue morphine
antinociception in mice rendered tolerant to this opioid (Vidal-
Torres et al., 2013; Rodríguez-Muñoz et al., 2015). Therefore,
sigma-1 antagonists are promising tools as opioid adjuvants
(Vela et al., 2015; Sánchez-Fernández et al., 2017), and in fact a
further potential indication for S1RA in human patients might
be to enhance opioid analgesia (Vela et al., 2015). Preclinical
findings on the enhancement of opioid antinociception by
sigma-1 inhibition have thus far been reported exclusively in
models of nociceptive pain. It is known that opioid receptor
functioning can change during inflammation (reviewed in
Stein et al., 2009); therefore, the mechanisms involved in
the modulation of opioid antinociception by sigma-1 receptor
may not be the same during inflammation as in conditions
not involving injury.
In light of these antecedents, we aimed to test whether
the sigma-1 receptor antagonist S1RA enhanced morphine
antinociception or modulated morphine analgesic tolerance
during inflammatory pain. We measured both the antiallodynic
effect of morphine as a measure of cutaneous sensory
hypersensitivity, and the recovery of grip strength deficits
induced by this opioid as a measure of the impact of pain
on physical function. As a control for the known effects of
sigma-1 antagonism on nociceptive pain, we also investigated
heat antinociception in animals without inflammation. This
allowed us to compare the effects of morphine, S1RA, and
their association on nociceptive heat pain, inflammatory
tactile allodynia and functional deficits (grip strength)
induced by inflammatory pain.
MATERIALS AND METHODS
Experimental Animals
Female CD1 mice (Charles River, Barcelona, Spain) were
used in all experiments. We choose female animals because
it has been reported that women may be at greater risk
for pain-related disability than men (e.g., Unruh, 1996;
Stubbs et al., 2010). Animals weighing 25–30 g were tested
randomly throughout the estrous cycle. This mouse strain
has been previously reported not to show variations in
opioid analgesia during the phases of the estrous cycle
(Mogil et al., 2000). All mice were housed in colony cages
with free access to food and water prior to the experiments,
and were kept in temperature- and light-controlled rooms
(22 ± 2◦C, 12-h light–dark cycle). The experiments were
performed during the light phase from 9:00 a.m. to 3:00 p.m.
Animal care was provided in accordance with institutional
(Research Ethics Committee of the University of Granada,
Granada, Spain), regional (Junta de Andalucía, Spain) and
international standards (European Communities Council
directive 2010/63). All mice were used in only one experimental
procedure (heat nociception, von Frey testing or grip
strength measurement).
CFA-Induced Periarticular Inflammation
To induce the inflammation, mice were injected periarticularly
with Complete Freund’s Adjuvant (CFA) (Sigma-Aldrich,
Madrid, Spain) according to a previously described method
(Montilla-García et al., 2017). In most experiments, CFA
was administered subcutaneously (s.c.) around the tibiotarsal
joint in two separate injections to the inner and outer side
of the joint, at a volume of 15 µL/injection (30 µL/paw) to
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obtain homogeneous inflammation. In some experiments
CFA was administered with the same procedure described
above but using a lower injection volume (5 µL/injection;
i.e., 10 µL/paw). Control animals received the same volume
of sterile physiological saline (0.9% NaCl) with the same
procedure. Injections were made with a 1710 TLL Hamilton
microsyringe (Teknokroma, Barcelona, Spain) and a 301/2-
gauge needle under isoflurane anesthesia (IsoVet R©, B.
Braun, Barcelona, Spain). Behavioral evaluations in mice
with induced inflammation were done 2 days after CFA
or saline injection, since we previously reported that both
tactile allodynia and grip strength deficits peak at this time
(Montilla-García et al., 2017). Inflammatory edema was
monitored by measuring ankle thickness with an electronic
caliper (Montilla-García et al., 2017), also 2 days after
CFA administration.
Drugs and Drug Administration
We used the opioid agonist morphine (supplied by the General
Directorate of Pharmacy and Drugs, Spanish Ministry of Health,
Spain). S1RA (4-[2-[[5-methyl-1-(2-naphthalenyl)1H-pyraol-
3-yl]oxy]ethyl] morpholine hydrochloride) (DC Chemicals,
Shanghai, China) was used as a selective sigma-1 antagonist
(Cobos et al., 2008; Romero et al., 2012). The dose of sigma-1
antagonist used in the present study (80 mg/kg) was high enough
to induce a maximal effect in several pain models (Nieto et al.,
2012; Sánchez-Fernández et al., 2013, 2014; Tejada et al., 2014,
2017). This same dose has been used in the formalin test (Romero
et al., 2012), and higher doses of this compound (128 mg/kg)
have been used in inflammatory heat hyperalgesia (Tejada et al.,
2014, 2017), neuropathic cold allodynia (Nieto et al., 2012),
and visceral pain (González-Cano et al., 2013). This last study
showed that the s.c. administration of S1RA at 128 mg/kg still
had selective analgesic effects (present in wild-type but absent
in sigma-1 knockout mice). PRE-084 ([2-(4-morpholinethyl) 1-
phenylcyclohexanecarboxylate hydrochloride]) (Tocris Cookson
Ltd., Bristol, United Kingdom) was used as a selective sigma-1
agonist (Hayashi and Su, 2004; Cobos et al., 2008). We used
half of the dose for PRE-084 than the dose used for S1RA
in all experiments (i.e., 40 mg/kg of PRE-084). This dose
was selected based in our previous experience in which we
usually use this proportion of PRE-084/S1RA to fully reverse
the effects of the sigma-1 antagonist (e.g., Sánchez-Fernández
et al., 2013, 2014). In addition, in some experiments we used
(+)-pentazocine (Sigma-Aldrich S.A.) as an additional selective
sigma-1 agonist (Hayashi and Su, 2004; Cobos et al., 2008).
All drugs were dissolved in sterile physiological saline (0.9%
NaCl); the PRE-084 solution was appropriately alkalinized with
NaOH. To evaluate the effects of systemic treatments, drugs
were injected s.c. into the interscapular zone in a volume of
5 mL/kg. When the effect of the association of two or more drugs
was tested, each drug was injected into a different area of the
interscapular zone.
In experiments on the acute effects of systemic morphine
alone or its association with S1RA, morphine was injected s.c.
30 min before the behavioral evaluation, and S1RA immediately
before morphine injection. When PRE-084 or (+)-pentazocine
were used to reverse the effect of S1RA, they were injected s.c.
5 min before S1RA.
Morphine tolerance was induced by a modification of the
protocol we used in a previous study (Vidal-Torres et al., 2013).
Briefly, morphine tolerance was induced with a 3-day cumulative
dosage regimen consisting of twice-daily s.c. injections (b.i.d.)
at 9:30 a.m. and 9:30 p.m., starting on day 1 at 9:30 a.m.
The individual doses were 30 mg/kg (a.m.) and 45 mg/kg
(p.m.) on day 1, 60 mg/kg (a.m.) and 80 mg/kg (p.m.) on
day 2, and 100 mg/kg (a.m.) and 120 mg/kg (p.m.) on day
3. To avoid tissue lesions by repeated injections, morphine
administration was rotated in each of the four quadrants of the
back of the mice.
To study whether S1RA administration was able to rescue
morphine antinociception from tolerance once the latter was fully
developed, on day 4, after the tolerance protocol was completed,
mice were randomized to receive a test dose of morphine s.c.
(4 mg/kg in tactile allodynia, and 8 mg/kg in heat nociception
and grip strength) alone or associated with S1RA (80 mg/kg, s.c.
for both tests), and then the behavioral effects were recorded
(Figure 1, Protocol I). As in the protocol used to explore the
acute effect of morphine alone and the influence of S1RA on the
effects of this opioid, morphine was administered immediately
after S1RA, 30 min before the behavioral evaluation. PRE-084 was
administered 5 min before S1RA.
To study whether S1RA was able to prevent the development
of morphine tolerance, mice were given S1RA (b.i.d. 80 mg/kg,
s.c.) immediately after each morphine injection during the
induction of analgesic tolerance (Figure 1, Protocol II). For each
set of injections, each drug was injected in a different area of the
interscapular zone according to the rotation protocol. Behavioral
testing was done on day 4 with the same doses of morphine as
reported in the preceding paragraph.
Injections of the drug solvent (saline) were used in all
cases as a control.
Measurement of Heat Nociception
(Unilateral Hot Plate)
Heat nociception was assessed as previously described
(Menéndez et al., 2002; Montilla-García et al., 2018). The
plantar side of the stimulated hind paw was placed on the
surface of a thermal analgesiometer (Model PE34, Series
8, IITC Life Science Inc., Los Angeles, CA, United States)
previously set at 55 ± 1◦C until the animal showed a paw
withdrawal response. The latency in seconds from paw
stimulation to the behavioral response was measured with
a digital chronometer. Only a clear unilateral withdrawal of
the paw was recorded as a nociceptive response. We avoided
simultaneous heat stimulation in both hind paws by placing
the plantar side of the tested hind paw on the hot plate while
the other hind paw was placed on filter paper (off the hot
plate) during observations (see Supplementary Video 2 in2
in Montilla-García et al., 2018). Two alternating evaluations
were done in each hind paw at intervals of 1 min between each
stimulation. A 50-s cut-off was used for each measurement to
prevent tissue damage. The mean value of the two averaged
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FIGURE 1 | Experimental protocols used to investigate the effect of S1RA on morphine tolerance. Morphine tolerance was induced with a 3-day cumulative dosage
regimen using the subcutaneous doses of morphine shown in the Figure. The upper panel shows the protocol used to test the effects of S1RA on rescue of the
effect of morphine from tolerance once it was fully developed. The lower panel shows the protocol to study the effect of S1RA on prevention of the development of
morphine tolerance. Drugs or their solvent (saline) were administered subcutaneously (s.c.). In all cases, “Evaluation” indicates the time when heat nociception, von
Frey threshold or grip strength was measured, which was always on day 4 after the first morphine administration. On the evaluation day all animals received a dose
of morphine (4 or 8 mg/kg sc. depending on the experiment; see text for details) 30 min before the pain response was evaluated.
measurements for each hind paw was used to analyze the
effects of treatments.
Measurement of von Frey Threshold
Tactile allodynia to a punctate stimulus was studied with the
method described in a previous publication (Cobos et al., 2018).
Briefly, animals were acclimated for 2 h in methacrylate test
compartments (7.5 cm wide× 7.5 cm long× 15 cm high) placed
on an elevated mesh-bottomed platform, to provide access to
the plantar surface of the hind paws. The von Frey stimulations
were applied to the heel, because our CFA injection protocol
led to inflammation and tactile allodynia most prominently in
this area (Montilla-García et al., 2017). A logarithmic series
of calibrated von Frey monofilaments (Stoelting, Wood Dale,
IL, United States), with bending forces that ranged from 0.02
to 1.4 g, were applied with the up–down paradigm (Chaplan
et al., 1994), starting with the 0.6-g filament. Filaments were
applied twice for 2–3 s, with between-application intervals of at
least 30 s to avoid sensitization to the mechanical stimuli. The
response to the filament was considered positive if immediate
licking or biting, flinching or rapid withdrawal of the stimulated
paw was observed.
Measurement of Grip Strength
Grip strength was measured with a computerized grip strength
meter (Model 47200, Ugo Basile, Varese, Italy) according to
the method reported previously (Montilla-García et al., 2017).
To measure grip strength in the hind paws, the experimenter
held the mouse gently by the base of the tail, allowing the
animal to grasp the metal bar of the grip strength meter
with its hind paws. The metal bar was connected to a force
transducer that automatically recorded the peak force of each
measurement in grams (g). Hind limb grip strength in each
mouse was measured in triplicate. To prevent mice from gripping
the metal bar with their forepaws during the recording, the
animals were first allowed to grasp a wire mesh cylinder with
their forepaws (see Supplementary Video in Montilla-García
et al., 2017). Baseline grip strength values were recorded for
each animal as the average of two determinations on different
days before the administration of CFA or saline. This value was
considered 100% of grip strength and used as a reference for
subsequent determinations.
Determination of the Concentration of
S1RA, Morphine and Morphine
3-Glucuronide in Plasma and Brain
Tissue
To study whether the effects of S1RA on morphine tolerance
were due to pharmacokinetic interactions between the sigma-1
antagonist and the opioid drug, we measured the concentration
in plasma and brain tissue of S1RA, morphine and morphine-
3-glucuronide, the major morphine metabolite in rodents
(Pasternak and Pan, 2013). The concentrations of these
compounds in plasma and brain tissue were measured
according to the time when the behavioral effects of drug
treatments were assessed, as described in the Section“Drugs
and Drug Administration.” Briefly, a terminal blood sample
was drawn from each mouse by cardiac puncture, at the
appropriate time after vehicle or compound dosing. Blood
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samples were collected in heparinized tubes and centrifuged
at 2,000 g for 10 min to obtain plasma. Immediately after
blood extraction, whole brains were removed. Plasma samples
and brains were stored at −80◦C until analysis. Each brain
was weighed and homogenized in 4 mL Dulbecco’s phosphate
buffered saline immediately before drug concentrations
were determined. Protein was precipitated with acetonitrile,
and samples were analyzed by high-performance liquid
chromatography–triple quadrupole mass spectrometry (HPLC-
MS/MS). The concentrations of compounds in plasma and
brain were determined by least-squares linear regression
with a calibration curve.
Data Analysis
The data were analyzed with the SigmaPlot 12.0 program
(Systat Software Inc., San Jose, CA, United States). One-way,
two-way, or two-way repeated-measures analysis of variance
(ANOVA) was used depending on the experiment; Student–
Newman–Keuls post hoc test was done in all cases. The
differences between means were considered significant when the
P-value was below 0.05.
RESULTS
Modulation by S1RA of
Morphine-Induced Antinociception to
Heat Stimulus
The paw withdrawal latency to a nociceptive heat stimulus
in mice without inflammation was short, i.e., less than 5s
(Figure 2A). Morphine administration (2–8 mg/kg, s.c.) induced
dose-dependent robust antinociceptive effects, reaching values of
about 30 s at the highest dose tested (Figure 2A).
In contrast to morphine, the selective sigma-1 antagonist
S1RA (80 mg/kg, s.c.) failed to alter the response latency of
mice to a nociceptive heat stimulus (Figure 2B). However,
when we associated this dose of S1RA with morphine 4 mg/kg
(s.c.), the response latency increased markedly (Figure 2B).
FIGURE 2 | Effects of morphine alone or associated with S1RA on nociceptive pain induced by heat stimulation. The results represent paw withdrawal latency
during stimulation of the hind paw at 55◦C. (A) Effect of the subcutaneous (s.c.) administration of different doses of morphine (2–8 mg/kg) or its vehicle. (B) Effect of
the s.c. administration of morphine (4 mg/kg), S1RA (80 mg/kg) or their vehicle; morphine (4 mg/kg) + S1RA (80 mg/kg), and the association of these drugs with
PRE-084 (40 mg/kg) or its vehicle. Each bar and vertical line represent the mean ± SEM of values obtained in 8–10 animals. (A) Statistically significant differences
between the values obtained in animals treated with morphine or its vehicle: ∗∗P < 0.01 (one-way ANOVA followed by Student–Newman–Keuls test). (B) Statistically
significant differences between the values obtained in animals treated with: morphine or its vehicle (∗P < 0.05, ∗∗P < 0.01); morphine + S1RA or its vehicle
(##P < 0.01); and morphine + S1RA associated with PRE-084 or its vehicle (P < 0.01) (one-way ANOVA followed by Student–Newman–Keuls test).
TABLE 1 | Summary of the main results for the role of sigma-1 receptors in nociceptive heat pain and inflammation-induced tactile allodynia and grip strength deficits.
Type of pain Stimulus Sensitivity to morphine Sensitivity to S1RA Potentiation of morphine
by S1RA





Nociceptive Heat + − + + −
Inflammatory von Frey +++ − + + −
Grip strength ++ + − + +
S1RA was always administered subcutaneously (s.c.) at 80 mg/kg. The doses of morphine used to test the potentiation of its effect by S1RA varied according to the
sensitivity to the opioid in each test (1 mg/kg for von Frey testing in mice with inflammation, and 2–4 mg/kg for nociceptive heat pain and grip strength deficits induced by
inflammation), and in the evaluation of analgesic tolerance (4 mg/kg for von Frey testing in mice with inflammation, and 8 mg/kg for nociceptive heat pain and grip strength
deficits induced by inflammation).
Frontiers in Pharmacology | www.frontiersin.org 5 February 2019 | Volume 10 | Article 136
fphar-10-00136 February 20, 2019 Time: 17:18 # 6
Montilla-García et al. Sigma-1 Receptors and Morphine Analgesia
S1RA also increased the antinociceptive effect induced by
morphine 2 mg/kg (s.c.), but to a lesser extent (data not
shown). We also evaluated the effects of the sigma-1 agonist
PRE-084 (40 mg/kg, s.c.) on heat antinociception induced
by the association of S1RA with morphine, and found that
treatment with the sigma-1 agonist abolished the S1RA-induced
potentiation of morphine antinociception (Figure 2B). When
PRE-084 was administered alone it failed to induce any effect
on nociception (data not shown). These results support the
selectivity of the effects induced by S1RA. Therefore, S1RA
appeared to enhance the antinociceptive effect of morphine to
a heat stimulus through sigma-1 inhibition. These results are
summarized in Table 1.
Modulation by S1RA of Tolerance to the
Antinociceptive Effect of Morphine in
Response to Heat Stimulus
Animals were rendered morphine-tolerant with a 3-day
escalating dosage regimen (Figure 1). Control non-tolerant
mice were treated with the morphine vehicle. On day 4,
non-tolerant mice showed a marked increase in the response
latency induced by a morphine dose shown in the previous
experiments (see section “Modulation by S1RA of Morphine-
Induced Antinociception to Heat Stimulus”) to induce evident
antinociception (8 mg/kg, s.c.) (Figure 3A, black bars). However,
the effect induced by this morphine dose was markedly lower
in morphine-tolerant mice, with a paw withdrawal latency
of 29.01 ± 3.67 s in non-tolerant mice vs. 9.25 ± 1.95 s in
tolerant mice in response to morphine (Figure 3A). In animals
rendered tolerant to morphine, we associated the administration
of S1RA (80 mg/kg, s.c.) to morphine (8 mg/kg, s.c.) according
to Protocol I in Figure 1, and found that the response latency
was longer, reaching times similar to those in control non-
tolerant mice. This result indicated that S1RA was able to rescue
morphine antinociception in tolerant animals (Figure 3A). The
administration of PRE-084 (40 mg/kg, s.c.) completely abolished
the increase in the antinociceptive effect of morphine induced by
S1RA in morphine-tolerant mice: the latency values were close
to those found in tolerant mice treated with morphine alone
on the day of the experiment (Figure 3A). When PRE-084 was
administered alone it failed to induce any effect on nociception
(data not shown).
We also tested whether the repeated administration of S1RA
(80 mg/kg, s.c.) before each dose of morphine during the 3-
day period of morphine administration had any pre-emptive
effect on the appearance of morphine tolerance to its effect on
nociceptive heat pain (according to Protocol II in Figure 1).
When the effect of morphine (8 mg/kg, s.c.) was tested on
day 4 without any further administration of S1RA, the effect
of morphine was lower (Figure 3B). These results indicated
that tolerance to the antinociceptive effect of morphine on the
response to a heat stimulus was present despite repeated pre-
emptive S1RA administration.
Therefore, sigma-1 receptor inhibition by S1RA was able
to restore the antinociceptive effect of morphine to heat
stimulation in mice tolerant to this opioid, but pre-emptive S1RA
treatment failed to affect the development of tolerance to the
effect of morphine on nociceptive heat pain. These results are
summarized in Table 1.
Modulation by S1RA of the Antiallodynic
Effect of Morphine During Inflammation
In mice with CFA injected around the tibiotarsal joint
(30 µL/paw), the mechanical pain threshold in the heel was
markedly reduced, denoting the presence of tactile allodynia
(0.73 ± 0.05 g and 0.06 ± 0.01 g in mice without and with
inflammation, respectively) (Figure 4A). Joint inflammation did
not induce alterations in the von Frey threshold in the non-
inflamed area (pad) of the paw (data not shown), indicating
that sensory alterations appeared to be restricted to the inflamed
area. Morphine administration (1–4 mg/kg, s.c.) induced a dose-
dependent antiallodynic effect in animals with inflammation,
and the normal mechanical threshold was fully recovered at the
highest dose tested (Figure 4A). The effect of morphine was
more prominent in tactile allodynia than in nociceptive heat pain:
the doses needed to induce significant effects were lower in the
former assay (compare Figures 2A, 4A).
The administration of S1RA alone (80 mg/kg, s.c.) did not
ameliorate inflammatory tactile allodynia (Figure 4B). However,
the association of this dose of S1RA with a low dose of
morphine (1 mg/kg, s.c.), which was also devoid of antiallodynic
effect per se, resulted in a marked synergistic increase in the
mechanical threshold in mice with induced inflammation: the
values in these animals were similar to those in mice in which
inflammation was not induced (Figure 4B). As reported above
for heat nociception, the administration of the sigma-1 agonist
PRE-084 (40 mg/kg, s.c.) abolished the potentiation induced by
S1RA of the antiallodynic effect of morphine (Figure 4B); this
result supports the notion that the effects induced by S1RA are
selective. We thus found that S1RA enhanced the antiallodynic
effect of morphine through sigma-1 inhibition. These results are
summarized in Table 1.
Interestingly, when this dose of S1RA (80 mg/kg, s.c.) was
assayed in mice with a lower degree of inflammation (10 µL
CFA/paw), it was able to fully recover the normal mechanical
threshold in mice with inflammation in the absence of morphine
administration (Supplementary Figure S1), indicating that
this compound is able to exert antiallodynic effects, albeit
in milder inflammation. The antiallodynic effect induced by
S1RA was abolished by PRE-084 (40 mg/kg, s.c.), a result
that supports the selectivity of the effects induced by S1RA
(Supplementary Figure S1).
Modulation by S1RA of Tolerance to the
Antiallodynic Effect of Morphine During
Inflammation
As described above for heat nociception, animals were
rendered morphine-tolerant with a 3-day escalating dosage
regimen (Figure 1), whereas control non-tolerant mice
received the morphine vehicle. On day 4, non-tolerant mice
with inflammation (30 µL CFA/paw) showed complete
reversion of inflammatory tactile allodynia induced by the acute
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FIGURE 3 | Modulation by S1RA of tolerance to the effect of morphine on nociceptive pain caused by heat stimulation. The results represent paw withdrawal latency
during stimulation of the hind paw at 55◦C. (A) Rescue of morphine tolerance by S1RA: animals were repeatedly treated during 3 days with morphine (tolerant, white
bars) or its vehicle (non-tolerant, black bars), according to Protocol I in Figure 1. On the day of evaluation (day 4) mice were treated subcutaneously (s.c.) with
morphine (8 mg/kg) or its vehicle, morphine (8 mg/kg) + S1RA (80 mg/kg) or its vehicle, or the combination of these drugs with PRE-084 (40 mg/kg) or its vehicle.
(B) Prevention of morphine tolerance by S1RA: animals were treated s.c. with S1RA (80 mg/kg) or its vehicle immediately before each dose of morphine (tolerant,
white bars) during the induction of morphine tolerance, according to Protocol II in Figure 1. Control mice (non-tolerant, black bars) received the vehicle of morphine
and S1RA during 3 days, according to Protocol II in Figure 1. On the day of evaluation (day 4) tolerant and non-tolerant mice were treated with morphine only
(8 mg/kg, s.c.) or its vehicle. Each bar and vertical line represent the mean ± SEM of the values obtained in 8–10 animals. (A,B) Statistically significant differences
between the values obtained in mice treated with morphine or its vehicle (∗∗P < 0.01), and between the values obtained in tolerant and non-tolerant animals treated
with morphine on the day of the evaluation (§§ P < 0.01) (one-way ANOVA followed by Student–Newman–Keuls test). (A) Statistically significant differences in
tolerant mice between the values obtained in mice treated on the day of evaluation with: morphine + S1RA or its vehicle (##P < 0.01); morphine + S1RA associated
with PRE-084 or its vehicle (P < 0.01) (one-way ANOVA followed by Student–Newman–Keuls test). (B) There were no statistically significant differences in the effect
of morphine on the day of evaluation between the values in mice treated with S1RA or its vehicle during the induction of morphine tolerance (two-way ANOVA
followed by Student–Newman–Keuls test).
FIGURE 4 | Effects of morphine alone or associated with S1RA on inflammatory mechanical allodynia. The results represent the 50% mechanical threshold
(determined with von Frey filaments) in mice treated periarticularly (30 µL/paw) with CFA or saline (S). (A) Effect of the subcutaneous (s.c.) administration of different
doses of morphine (1–4 mg/kg) or its vehicle. (B) Effect of the s.c. administration of morphine (1 mg/kg), S1RA (80 mg/kg) or its vehicle; morphine (1 mg/kg) + S1RA
(80 mg/kg), and the association of these drugs with PRE-084 (40 mg/kg) or its vehicle. Each bar and vertical line represent the mean ± SEM of values obtained in
8–10 animals. (A,B) Statistically significant differences between the values obtained in: animals with and without inflammation (ψψP < 0.01); animals treated with
morphine or its vehicle (∗∗P < 0.01) (one-way ANOVA followed by Student–Newman–Keuls test). (B) Statistically significant differences between the values obtained
in animals with inflammation treated with: morphine + S1RA or its vehicle (##P < 0.01); morphine + S1RA associated with PRE-084 or its vehicle. # (P < 0.01)
(one-way ANOVA followed by Student–Newman–Keuls test).
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FIGURE 5 | Modulation by S1RA of tolerance to the effect of morphine on inflammatory mechanical allodynia. The results represent the 50% mechanical threshold
(determined with von Frey filaments) in mice treated periarticularly (30 µL/paw) with CFA or saline (S). (A) Rescue of morphine tolerance by S1RA: Animals were
repeatedly treated during 3 days with morphine (tolerant, white bars) or its vehicle (non-tolerant, black bars), according to Protocol I in Figure 1. On the day of
evaluation (day 4) mice were treated subcutaneously (s.c.) with morphine (4 mg/kg) or its vehicle, the combination of morphine (4 mg/kg) and S1RA (80 mg/kg) or its
vehicle, and the combination of these drugs with PRE-084 (40 mg/kg) or its vehicle. (B) Prevention of morphine tolerance by S1RA: Animals were treated s.c. with
S1RA (80 mg/kg) or its vehicle immediately before each dose of morphine (tolerant, white bars) during the induction of morphine tolerance, according to Protocol II in
Figure 1. Control mice (non-tolerant, black bars) received the vehicles of morphine or S1RA during 3 days, according to Protocol II in Figure 1. On the day of
evaluation (day 4), tolerant and non-tolerant mice were treated s.c. with morphine only (4 mg/kg) or its vehicle. Each bar and vertical line represent the mean ± SEM
of the values obtained in 8–10 animals. (A,B) Statistically significant differences between the values obtained in: mice with and without inflammation that received the
same treatment (ψψP < 0.01); tolerant and non-tolerant animals treated with morphine on the day of the evaluation (§§ P < 0.01); mice treated with saline or
morphine on the day of evaluation (∗∗P < 0.01) (one-way ANOVA followed by Student–Newman–Keuls test). (A) Statistically significant differences in tolerant mice
between the values obtained in animals treated on the day of evaluation with: morphine + S1RA or its vehicle (##P < 0.01); morphine + S1RA associated with
PRE-084 or its vehicle (P < 0.01) (one-way ANOVA followed by Student–Newman–Keuls test). (B) There were no statistically significant differences in the effect of
morphine on the day of evaluation between mice treated with S1RA or its vehicle during the induction of morphine tolerance (two-way ANOVA followed by
Student–Newman–Keuls test).
administration of morphine 4 mg/kg (s.c.) (Figure 5A, black
bars). However, in morphine-tolerant mice the antiallodynic
effect induced by the same morphine dose was markedly
lower, with a mechanical threshold of 0.73 ± 0.09 g in
non-tolerant mice vs. 0.27 ± 0.11 g in tolerant mice with
inflammation in response to morphine (Figure 5A). In
animals rendered tolerant to morphine, we associated the
administration of S1RA (80 mg/kg, s.c.) to morphine (4 mg/kg,
s.c.) according to Protocol I in Figure 1, and found that the
mechanical threshold was higher and similar to that found
in non-tolerant mice with inflammation treated with this
opioid drug (Figure 5A). These results indicate that S1RA
was able to rescue the antiallodynic effect of morphine in
tolerant animals. The administration of PRE-084 (40 mg/kg,
s.c.) completely abolished the effect of S1RA in morphine-
treated tolerant mice, yielding values close to those found
in tolerant mice treated with morphine alone on the day of
the experiment (Figure 5A).
We also tested whether the repeated administration of S1RA
(80 mg/kg, s.c.) before each dose of morphine during the
3-day regimen of morphine administration had a pre-emptive
effect on the development of morphine tolerance to its
antiallodynic effect (according to Protocol II in Figure 1).
When the effect of morphine (4 mg/kg, s.c.) was tested
on day 4 without any further administration of S1RA,
the effect of morphine was reduced (Figure 5B). These
results indicate that tolerance to the antiallodynic effect
of morphine appeared despite the repeated pre-emptive
administration of S1RA.
Therefore, as in the results for heat nociception, sigma-1
receptor inhibition by S1RA was able to restore the morphine-
induced antiallodynic effects in mice with inflammation
tolerant to this opioid, but pre-emptive treatment with
S1RA failed to affect the development of tolerance to
the antiallodynic effect of morphine. These results are
summarized in Table 1.
Absence of Modulation by S1RA of
Morphine-Induced Recovery of Grip
Strength Deficits During Inflammation
Mice in which saline was injected periarticularly (30 µL/paw)
showed grip strength values close to 100% of their baseline
values, whereas in mice with joint inflammation induced
by the injection of the same volume of CFA, grip strength
was reduced to about half of its baseline value (Figure 6A,
first two bars). Morphine administration (2–8 mg/kg,
s.c.) induced a dose-dependent recovery of grip strength
deficits in animals with inflammation, and the highest
dose tested led to full recovery of normal grip strength
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FIGURE 6 | Effects of morphine alone or associated with S1RA on grip strength deficits induced by inflammation. The results represent the grip strength values,
expressed as the average percentage of the baseline value in each individual mouse before the periarticular injection (30 µL/paw) with CFA or saline (S), (A) effect of
the subcutaneous (s.c.) administration of different doses of morphine (2–8 mg/kg) or its vehicle. (B) Effect of the s.c. administration of morphine (2 or 4 mg/kg), S1RA
(80 mg/kg) or its vehicle, and the association of morphine (2 or 4 mg/kg) with S1RA (80 mg/kg). Each bar and vertical line represent the mean ± SEM of values
obtained in 8–10 animals. (A,B) Statistically significant differences between the values obtained in mice with and without inflammation: ψP < 0.05, ψψP < 0.01; and
between animals with inflammation treated with morphine or its vehicle: ∗P < 0.05, ∗∗P < 0.01 (one-way ANOVA followed by Student–Newman–Keuls test).
(B) There were no statistically significant differences between the values obtained in mice treated with morphine + S1RA or its vehicle (one-way ANOVA followed by
Student–Newman–Keuls test).
values (Figure 6A). Morphine was less potent in reversing
grip strength deficits than in inhibiting tactile allodynia
during inflammation, and both endpoints were more
sensitive to morphine than nociceptive heat pain (compare
Figures 2A, 4A, 6A).
The administration of S1RA alone (80 mg/kg, s.c.) induced
a slight but significant increase in grip strength values in
mice with inflammation (Figure 6B). In contrast to the results
for heat nociception and inflammatory tactile allodynia, S1RA
administration did not enhance the effect of morphine at
either 2 or 4 mg/kg (s.c.) (Figure 6B). To further confirm
the lack of effect of S1RA on the effect of morphine on grip
strength in mice with inflammation, we performed a time-
course study of the drug effects. The association of S1RA
with morphine did not alter the effect of this opioid drug
administered at 2 mg/kg (s.c.) at any time-point tested between
30 and 180 min after drug administration (Supplementary
Figure S2A). Similar results were found when we tested the
effects of the association of S1RA with morphine 4 mg/kg (s.c.)
(Supplementary Figure S2B).
Therefore, in contrast to the potentiation by S1RA of
morphine-induced heat antinociception and the antiallodynic
effects in mice with inflammation, S1RA was unable
to modify the effects of morphine on grip strength
deficits induced by joint inflammation. These results are
summarized in Table 1.
Modulation by S1RA of Tolerance to
Morphine-Induced Recovery of Grip
Strength Deficits During Inflammation
Animals were rendered morphine-tolerant by the same
procedure described in previous sections (Figure 1), whereas
control non-tolerant mice received morphine vehicle. In
non-tolerant mice with inflammation (30 µL CFA/paw), grip
strength deficits were markedly reversed in response to the
acute administration of morphine 8 mg/kg (s.c.) (Figure 7A,
black bars). However, the same morphine dose (8 mg/kg,
s.c.) in morphine-tolerant mice had no significant effect on
grip strength, which was about half of the baseline value
(83.95 ± 4.8% in non-tolerant mice vs. 57.81 ± 4.2% in tolerant
mice with inflammation in response to morphine) (Figure 7A).
In animals rendered tolerant to morphine, we associated the
administration of S1RA (80 mg/kg, s.c.) to morphine (8 mg/kg,
s.c.) according to Protocol I in Figure 1, and found that grip
strength reached values close to 80% of baseline measurements
(Figure 7A). The administration of PRE-084 (40 mg/kg, s.c.)
or (+)-pentazocine (8 mg/kg, s.c.) completely abolished the
effect of the association of S1RA + morphine administered
to morphine-treated tolerant mice, with values close to those
in tolerant mice treated with morphine alone the day of the
experiment (Figure 7A). These results support the selectivity of
S1RA-induced effects.
We also tested whether the repeated administration of
S1RA (80 mg/kg, s.c.) during the 3-day regimen of morphine
administration (according to Protocol II in Figure 1) had a pre-
emptive effect on the development of morphine tolerance to
its effect on grip strength deficits. The repeated administration
of S1RA, when mice were evaluated the day after the
last S1RA administration, did not affect grip strength in
morphine-tolerant mice with inflammation. However, when
morphine (8 mg/kg, s.c.) was administered to these mice
on the evaluation day, the effect in response to the opioid
was robust (Figure 7B). These results indicate that S1RA
was able to prevent morphine tolerance in this particular
outcome, in contrast to the results for nociceptive heat
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FIGURE 7 | Modulation by S1RA of tolerance to the effect of morphine on grip strength deficits induced by inflammation. The results represent the grip strength
values, expressed as the average percentage of the baseline value in each individual mouse before the periarticular injection, (30 µL/paw) with CFA or saline (S).
(A) Rescue of morphine tolerance by S1RA: Animals were repeatedly treated subcutaneously (s.c.) during 3 days with morphine (tolerant, white bars) or its vehicle
(non-tolerant, black bars), according to Protocol I in Figure 1. On the day of evaluation (day 4) mice were treated s.c. with morphine (8 mg/kg) or its vehicle;
morphine (8 mg/kg) + S1RA (80 mg/kg) or its vehicle, and the combination of these drugs with PRE-084 (40 mg/kg), (+)-pentazocine [(+)-PTZ] or their vehicle.
(B) Prevention of morphine tolerance by S1RA: animals were treated s.c. with S1RA (80 mg/kg) or its vehicle immediately before each dose of morphine (tolerant,
white bars) during the induction of morphine tolerance, according to Protocol II in Figure 1. Control mice (non-tolerant, black bars) received the vehicle of morphine
or S1RA during 3 days, according to Protocol II in Figure 1. On the day of evaluation (day 4), tolerant and non-tolerant mice were treated with morphine only
(8 mg/kg, s.c.) or its vehicle. Each bar and vertical line represent the mean ± SEM of the values obtained in 8–10 animals. (A,B) Statistically significant differences
between the values obtained in: mice with and without inflammation that received the same treatment (ψψP < 0.01); tolerant and non-tolerant animals treated with
morphine on the day of the experiment (§§ P < 0.01); mice treated with saline or morphine on the day of behavioral testing (∗∗P < 0.01); tolerant mice treated with
S1RA or its vehicle either on the day of the evaluation or as pre-emptive treatment (##P < 0.01) (one-way ANOVA followed by Student–Newman–Keuls test).
(A) Statistically significant differences between the values obtained in tolerant mice treated on the day of evaluation with morphine + S1RA associated with PRE-084,
(+)-PTZ or their solvent: # P < 0.01 (two-way ANOVA followed by Student–Newman–Keuls test).
pain and inflammatory tactile allodynia reported in the
preceding sections.
Therefore the administration of S1RA, either when morphine
tolerance was fully developed or during the induction of
tolerance, was able to preserve the effect of morphine on grip
strength deficits in mice with joint inflammation. These results
are summarized in Table 1.
Morphine, S1RA and PRE-084 do Not
Alter Normal Grip Strength or
CFA-Induced Inflammatory Edema
We also tested whether the drugs used in the present
study altered grip strength in mice without inflammation.
The doses of morphine or S1RA (administered acutely
or repeatedly) used in this study, as well as the acute
administration of PRE-084 (at the dose used in our study),
did not alter normal grip strength in animals without
inflammation (Figure 8). These results suggest that the
effects on grip strength in mice with inflammation, reported
in the preceding section, were not due to the alteration of
normal motor function.
We also tested whether the drugs used in the present study
reduced inflammatory edema, by measuring changes in ankle
thickness in response to CFA administration. CFA injection
produced a marked increase in ankle thickness in comparison to
saline-treated mice, and this increase was not significantly altered
by either the acute administration of morphine (8 mg/kg, s.c.)
or the acute or repeated administration of S1RA (80 mg/kg, s.c.)
(Figure 9). Therefore, none of these drugs appeared to have an
antiedematous effect on CFA-induced inflammation.
Pharmacokinetic Interaction Between
S1RA and Morphine Does Not Affect
Their Concentrations in Plasma or Brain
Tissue
After a single administration of S1RA (80 mg/kg, s.c.), the
concentration of this sigma-1 antagonist was higher in brain
tissue than in plasma (compare black bars in the left panels
of Figures 10A,B). The repeated administration of morphine
according to our protocol for the induction of tolerance did
not alter the concentration of acutely administered S1RA
(80 mg/kg, s.c., according to Protocol I in Figure 1) in
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FIGURE 8 | Absence of effects of morphine, S1RA and PRE-084 on grip
strength in mice without inflammation. The results represent the grip strength
values (expressed as the average percentage of the baseline value in each
individual mouse before drug administration). Animals were treated
subcutaneously (s.c.) with morphine (8 mg/kg,), S1RA (80 mg/kg) or PRE-084
(40 mg/kg) on the day of the experiment, or treated twice daily with morphine
at escalating doses or with S1RA (80 mg/kg) during the 3 days before the
behavioral evaluation (see section “Materials and Methods” for details). Each
bar and vertical line represent the mean ± SEM of the values obtained in 8
animals. There were no statistically significant differences between values from
untreated animals and drug-treated mice (one-way ANOVA).
either plasma or brain tissue (compare black and white bars
in the left panels of Figures 10A,B). When we measured
the concentration of S1RA after its repeated administration
(80 mg/kg, s.c.) during the 3-day regimen of morphine
administration, without any further S1RA injection on the day
of plasma and brain collection (according to Protocol II in
Figure 1), we observed no appreciable levels of this sigma-
1 antagonist in any sample analyzed (see far-right bars in
the left panels of Figures 10A,B for plasma and brain levels,
respectively). Therefore, when S1RA was administered pre-
emptively during the induction of morphine tolerance, there was
no remaining S1RA in plasma or brain tissue at the time of the
behavioral evaluations.
Morphine levels were higher in plasma than in brain tissue
after the acute administration (8 mg/kg, s.c.) of this opioid
(compare black bars in the middle panels of Figures 10A,B).
Repeated morphine administration according to our protocol for
the induction of morphine tolerance did not change morphine
levels after the administration of this opioid on the day of
FIGURE 9 | Effects of morphine and S1RA on ankle thickness in mice with
inflammation. The results represent ankle thickness after the administration of
CFA or saline (S). Animals were treated subcutaneously (s.c.) with morphine
(8 mg/kg,) or S1RA (80 mg/kg) on the day of the experiment, or treated twice
daily with S1RA (80 mg/kg) during the 3 days before the evaluation (see
section “Materials and Methods” for details). Each bar and vertical line
represent the mean ± SEM of the values obtained in 8 animals. The
differences between the values from mice without or with inflammation were
statistically significant (99P < 0.01). There were no statistically significant
differences between the values from mice with inflammation treated with the
drugs and untreated mice with inflammation (one-way ANOVA followed by
Student–Newman–Keuls test).
sample collection in either plasma or brain tissue (compare
black bar and the first white bar in the middle panels of
Figures 10A,B). The acute or repeated administration of S1RA
(80 mg/kg, s.c. according to Protocol I or II in Figure 1) did
not alter morphine levels in either plasma or brain tissue in
morphine-tolerant animals (see white bars in the middle panels
of Figures 10A,B).
Like morphine, the concentration of morphine-3-glucuronide
was higher in plasma than in brain tissue (compare black
bars in the right panels of Figures 10A,B). This morphine
metabolite was more abundant than the parent compound in
both plasma and brain tissue after acute morphine administration
(compare black bars in the middle and right panels of
Figures 10A,B for plasma and brain tissue determinations,
respectively). Repeated morphine administration according to
our protocol to induce tolerance did not alter morphine-3-
glucuronide levels in either plasma or brain samples after
the administration of morphine on the day of the behavioral
evaluation (compare black bar and the first white bar in
the right panels of Figures 10A,B). The acute or repeated
administration of S1RA (80 mg/kg, s.c.) did not alter morphine-
3-glucuronide levels in morphine-tolerant animals in either
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FIGURE 10 | S1RA and morphine did not interact pharmacokinetically in a way that affected their concentrations in plasma or brain tissue. The levels of S1RA,
morphine and morphine-3-glucuronide were measured by ultra-high performance liquid chromatography and tandem mass spectrometry in plasma (A) and brain
homogenates (B). Animals were repeatedly treated subcutaneously (s.c.) during 3 days with morphine (tolerant, white bars) or its vehicle (non-tolerant, black bars).
On the day of sample collection (day 4) mice were treated s.c. with morphine (8 mg/kg) or its vehicle. S1RA (80 mg/kg, s.c.) was administered acutely on the day of
sample collection (according to Protocol 1 in1 in Figure 1), or immediately before each dose of morphine during the induction of morphine tolerance (according to
Protocol II in Figure 1). Each bar and vertical line represent the mean ± SEM of the values obtained in 5 animals. Statistically significant differences between the
concentrations of S1RA, morphine or morphine-3-glucuronide in vehicle-treated animals and the rest of the experimental groups tested (∗∗P < 0.01). There were no
statistically significant differences between the levels of S1RA when administered on the day of sample collection to morphine tolerant and non-tolerant animals; the
levels of morphine when administered on the day of sample collection to morphine tolerant and non-tolerant animals, or between the levels of
morphine-3-glucuronide when morphine was administered on the day of sample collection to morphine tolerant and non-tolerant animals (two-way ANOVA followed
by Student–Newman–Keuls test).
plasma or brain tissue (white bars in the right panels
of Figures 10A,B).
DISCUSSION
We compared the effects of morphine, S1RA and their
association on three different pain measures: nociceptive heat
pain, inflammatory tactile allodynia, and grip strength deficits
induced by inflammation. In addition, we studied the effects of
S1RA on morphine tolerance in these three different measures.
Our findings show that morphine was able to induce analgesic-
like effects on nociceptive heat pain, inflammatory tactile
allodynia and grip strength deficits induced by inflammation.
However, the sensitivity to this opioid drug varied depending
on the endpoint examined. Inflammatory allodynia and grip
strength deficits induced by inflammation were more sensitive
to the effects of morphine than nociceptive heat pain. These
results are consistent with the widely reported increase in the
effects of opioids on cutaneous sensory hypersensitivity during
inflammation (reviewed in Stein et al., 2009), and indicate that the
enhancement of opioid effects during inflammation, as observed
in von Frey filament thresholds, is also evident in the functional
deficit associated with this pathological condition. In previous
work we compared the pharmacological characteristics of grip
strength deficits and tactile allodynia during inflammation
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using several drugs from different pharmacological groups,
including opioids (oxycodone and tramadol), non-steroidal
anti-inflammatory drugs (ibuprofen and celecoxib), and
acetaminophen (Montilla-García et al., 2017). Interestingly, with
the exception of oxycodone, which showed a similar potency in
reversing tactile allodynia and grip strength deficits, the dose
of all other known analgesic drugs was lower for functional
deficits than for cutaneous hypersensitivity (Montilla-García
et al., 2017). Here we show that morphine was less potent in
reversing grip strength deficits than tactile allodynia, which
supports the notion that the pharmacological sensitivity of
these two outcomes during inflammation is not identical.
Differences between the analgesic sensitivity of standard
cutaneous measures of pain and pain-induced functional deficits
have been described previously for other outcomes used to test
pain interference on physical function, such as inflammation-
induced weight bearing differences or wheel running depression
(reviewed in Cobos and Portillo-Salido, 2013).
We also tested the effects of S1RA (in the absence of
morphine) on nociceptive heat pain, inflammatory tactile
allodynia and grip strength deficits induced by inflammation.
S1RA did not alter nociceptive heat pain, as previously reported
for this and other sigma-1 antagonists (e.g., Chien and Pasternak,
1994, 1995; Tejada et al., 2014, 2017). Here we show that
this sigma-1 antagonist was able to markedly ameliorate
sensory hypersensitivity during mild inflammation, as previously
reported (Parenti et al., 2014; Gris et al., 2015; Tejada et al.,
2018), but it was devoid of effect when inflammation was more
prominent (at a higher dose of CFA). We previously reported
a clear relationship between ankle thickness and the volume of
CFA administered (Montilla-García et al., 2017). We needed to
use a higher dose of CFA in our study because the decreases
in grip strength induced by lower doses of this compound were
too small to reliably assess the effects of analgesic drugs, as
we previously reported (Montilla-García et al., 2017). Therefore,
the experimental conditions used here to induce inflammatory
allodynia were too restrictive to detect the antiallodynic
effects induced by sigma-1 antagonism. Despite the absence of
effect of S1RA on inflammatory tactile allodynia during this
more prominent inflammation, here we show that S1RA was
able to partially ameliorate grip strength deficits induced by
inflammation, which again indicates that the sensitivity to drug
effects differs between tactile allodynia and grip strength deficits.
We have previously shown that both nociceptive heat pain
and tactile allodynia during inflammation in our experimental
conditions are sensitive to the in vivo ablation of transient
receptor potential vanilloid (TRPV1)-expressing neurons by
resiniferatoxin (Montilla-García et al., 2017, 2018). However,
grip strength deficits during inflammation are insensitive to
resiniferatoxin treatment (Montilla-García et al., 2017). These
results indicate that the neurobiological mechanisms involved in
grip strength deficits during inflammation and in the behavioral
tests of cutaneous sensitivity explored here are different.
Therefore, the effect of S1RA on grip strength deficits in mice
with inflammation may be due to sigma-1 actions in other pain
pathways unrelated to those involved in heat nociceptive pain or
inflammatory tactile allodynia.
In this study we show that the systemic administration of
S1RA was able to enhance morphine antinociception to contact
heat stimulation, in agreement with previous reports which used
other types of nociceptive heat stimulus (reviewed in Sánchez-
Fernández et al., 2017). We show that S1RA markedly potentiated
the antiallodynic effect of morphine in mice with inflammation.
To our knowledge this is the first reported evidence that
sigma-1 antagonism enhances the effect of an opioid drug in
a pathological pain model. The enhancement by S1RA of the
effects of morphine on nociceptive heat pain and inflammatory
tactile allodynia was abolished by the administration of the
sigma-1 agonist PRE-084, which argues in favor of an action
mediated by sigma-1 receptors in these S1RA-induced effects.
Despite the evident increase in the effects of morphine on
nociceptive heat pain and inflammatory tactile allodynia noted
above, and despite the greater sensitivity of grip strength
deficits to the effects of S1RA when administered alone (in
the absence of morphine), we show that S1RA was not able
to potentiate the effects of morphine on grip strength deficits
induced by inflammation. This result further supports the notion
that different neurobiological mechanisms are involved in grip
strength deficits and cutaneous pain.
We also explored the modulation of morphine analgesic
tolerance by S1RA, given that this unavoidable opioid effect
is a substantial drawback to the use of opioid analgesics
(Morgan and Christie, 2011). We found that when S1RA was
administered to morphine-tolerant mice, it was able to rescue
the effect of morphine on nociceptive pain in response to
contact heat stimulus, in agreement with previous studies that
used nociceptive heat stimulation (Vidal-Torres et al., 2013;
Rodríguez-Muñoz et al., 2015). We also show that S1RA was
able to rescue the effects of morphine on inflammatory tactile
allodynia. The rescue of morphine tolerance by this sigma-1
antagonist in heat nociception or inflammatory tactile allodynia
was abolished by the administration of PRE-084, which again
argues in favor of a role for an action mediated by sigma-1
receptors in the effects induced by S1RA. The association of
S1RA and morphine administered on the day of the behavioral
evaluation to morphine-tolerant animals also induced a clear
recovery of grip strength deficits. It is worth pointing out
the possibility that not all the effect detected in morphine-
tolerant animals that received S1RA + morphine on the
day of the experiment were due to the rescue of morphine
tolerance; given that S1RA had a slight but significant effect
on grip strength in mice with inflammation, this might have
contributed to the effect observed. We show that this effect of
S1RA + morphine in tolerant animals was reversed not only by
the administration of PRE-084, but also by the administration
of (+)-pentazocine, another selective sigma-1 agonist (Cobos
et al., 2008), which further supports the selectivity of the effects
induced by S1RA.
These results on the rescue of morphine tolerance by S1RA
cannot be explained by pharmacokinetic interactions that might
increase the level of morphine or its major murine metabolite
morphine-3-glucuronide (Pasternak and Pan, 2013), since we
found that the levels of these compounds remained unaltered
after acute S1RA administration in tolerant animals. Our
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results point instead to pharmacodynamic interactions between
sigma-1 antagonism and opioid effects. Interestingly, plasma
levels of S1RA in our mice were similar to plasma levels
of this drug found in humans after oral S1RA treatment at
therapeutic doses (Abadias et al., 2013; Bruna et al., 2018).
To study whether the administration of S1RA was able to
prevent the development of morphine tolerance, we administered
this sigma-1 antagonist during an escalating morphine dosage
regimen (but not on the day of the behavioral evaluation).
We found that, as previously reported, the repeated, pre-
emptive administration S1RA failed to prevent tolerance to
the effects of morphine on a nociceptive heat stimulus (Vidal-
Torres et al., 2013). In addition, sigma-1 antagonism also failed
to prevent tolerance to the antiallodynic effect of morphine
during inflammation. The repeated administration of S1RA
did not alter grip strength in morphine-tolerant animals with
inflammation, although surprisingly, it completely prevented the
development of tolerance to the effect of morphine on grip
strength deficits. Therefore, the effects induced by S1RA in
the preemptive protocol cannot be attributed to the effects of
this compound alone. Interestingly, we found that at the time
of the behavioral tests, the levels of morphine or morphine-
3-glucuronide remained unaltered in S1RA-treated mice and
there was no remaining S1RA in either plasma or brain tissues.
These results indicate that S1RA, when repeatedly administered
with morphine, is able to induce protective effects against the
development of tolerance.
It has been suggested that sigma-1 antagonism both
potentiates opioid analgesia and diminish morphine
tolerance by decreasing the inhibition of µ-opioid
receptors by N-methyl-d-aspartate receptor (NMDAR)
activity (Rodríguez-Muñoz et al., 2015). Because S1RA
failed to enhance the effect of morphine on grip strength
deficits during inflammation in non-tolerant mice but
was able to successfully prevent morphine tolerance in
this outcome, the mechanisms for opioid potentiation
by sigma-1 receptors appear to be dissociated from the
effects on opioid tolerance, at least in this measure of
pain-induced functional impairment.
It has been reported that the sigma-1 antagonists S1RA and
BD-1063 prevent paclitaxel-induced neuropathic pain (Nieto
et al., 2012, 2014), which points to broader neuroprotective effects
of sigma-1 antagonism. However, it remains unclear why this
prevention of morphine tolerance by S1RA affects only grip
strength deficits but not heat nociception or inflammatory tactile
allodynia. Although the mechanisms of cutaneous sensitivity
have been extensively explored for decades, little is known about
the mechanisms of pain-induced functional impairment, which
may not fully overlap (Cobos and Portillo-Salido, 2013; Montilla-
García et al., 2017; Negus, 2018). Similarly, the mechanisms
of opioid analgesic tolerance might also depend on the pain
measure used. Regardless of the exact mechanisms involved in
the differential results obtained in grip strength deficits and the
other two pain measures explored in the present study, in light of
our results it is clear that they are not fully equivalent.
Interestingly, neither the acute administration of morphine
nor the acute or repeated administration of S1RA were able
to alter CFA-induced inflammatory edema. The results with
S1RA are in agreement with a previous study showing that
this sigma-1 antagonist did not alter carrageenan-induced
inflammatory edema (Gris et al., 2014; Tejada et al., 2014).
Therefore, taking into account the amelioration of grip
strength deficits by the drugs tested here but their lack of
effects on inflammatory edema, our results suggest that their
effects on grip strength are not attributable to improved
grip strength resulting from reduced swelling around the
joints or tendons, and that swelling per se does not prevent
movement. Furthermore, grip strength is classically used
to assess neurotoxi in rodents, and is included in the
Irwin screen (Irwin, 1968; Mattsson et al., 1996), which is
ingrained in the pharmaceutical industry as the first tier of
preclinical testing to detect drug-induced neurotoxic effects
(Moser, 2011). We show that morphine or S1RA (administered
acutely or repeatedly), as well as the acute administration
of PRE-084, did not alter grip strength in animals without
inflammation, suggesting that the doses used in our study did
not alter normal motor function. Taken together, our results
suggest that the drugs tested here exert their effects through
pain modulation rather than through unspecific effects on
inflammation or motor performance.
Although von Frey testing, the behavioral assay currently used
most widely in preclinical pain research, is undoubtedly useful
to detect sensory alterations in patients with neuropathy (e.g.,
Bennett, 2001; Bouhassira et al., 2005; Moharic et al., 2012), it
is almost never used in other human pain conditions such as
rheumatic disease. Therefore, although von Frey testing has been
established as the standard in preclinical pain testing, it is not
a widely used pain measure in patients with non-neuropathic
chronic painful diseases. On the other hand, grip strength has
been widely and routinely evaluated for decades as a functional
measure in patients with joint inflammation caused by rheumatic
disease (e.g., Bijlsma et al., 1987; Pincus and Callahan, 1992;
Lee, 2013), and it is known to correlate with pain (Callahan
et al., 1987; Fraser et al., 1999; Overend. T. J et al., 1999). In
fact, one set of consensus-based recommendations advocates
measuring physical function as one of the main outcomes in
clinical trials of pain treatments (Dworkin et al., 2008). In light
of the differences we observed in the effects of sigma-1 receptors
on opioid analgesia and tolerance, as reflected in grip strength
tests and the measures of cutaneous sensitivity explored in
the present study, we believe measures of physical functioning
merit inclusion in the standard repertoire of behavioral tests in
preclinical laboratories, to better approximate the human pain
phenotype in preclinical pain research.
We conclude that sigma-1 receptors play a pivotal role in
the control of morphine analgesia and tolerance, albeit in a
manner dependent on the type of painful stimulus explored.
These findings may have important therapeutic implications for
the use of sigma-1 antagonists as opioid adjuvants. In addition,
the results we obtained for grip strength deficit as a surrogate
pain measure were not equivalent to those seen when standard
measures of cutaneous sensitivity were used. Further studies are
needed to fully understand the mechanisms through which pain
interferes with physical function.
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